David Shaw’s Guardant Health GH Stock Holding History

David Shaw’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$495K	Buy	+3,300	New	+$359K	﹤0.01%	4186
2025 Q4	–	Sell	-11,600	Closed	-$725K	–	4738
2025 Q3	$725K	Buy	+11,600	New	+$631K	﹤0.01%	3660

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

David Shaw's GH Position: Q2 2026 in Review

David Shaw increased its Guardant Health (GH) stake by 194% in Q2 2026, buying an estimated $90.1M and bringing the position to 1,255,658 shares worth $188M. The position accounts for 0.09% of the portfolio, ranked #235.

David Shaw first reported a position in GH in Q1 2020 and has held it in 15 quarters since. 595 funds tracked by Wall St. Rank hold GH as of Q2 2026.

David Shaw held 1,255,658 shares of Guardant Health worth $188M as of Q2 2026.
David Shaw bought 828,183 Guardant Health shares in Q2 2026, an estimated $90.1M.
Guardant Health made up 0.09% of David Shaw's portfolio in Q2 2026, its #235 holding.
David Shaw first reported a position in Guardant Health in Q1 2020 and has held it in 15 quarters since.
595 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.